Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer
When the bladder is removed for bladder cancer, pelvic lymph nodes (LN) are also removed. While the anatomic extent of this LN dissection is critical, the investigators often use the number of LN removed as a measure of the extent, which in turn is essential for determining the patient's further treatment and prognosis. The LN count, however, is also dependent on the pathologist's processing of the LN tissue, and the standards for this processing are poorly defined. The goal of this study is to establish a standardized method for processing and analyzing lymph node specimens. The investigators hypothesize that if an organic solvent is used to remove excess fat from the lymph nodes that the investigators will discover more clinically significant nodes in a more reproducible fashion when compared to the current method.
Transitional Cell Carcinoma
|Study Design:||Time Perspective: Prospective|
|Official Title:||Standardising an Approach for Analysis of Lymph Node Specimens From Radical Cystectomy With Pelvic Lymph Node Dissection Through the Use of an Organic Fat-emulsifying Agent|
- Proportion of patients with lymph node metastasis on pathologic examination [ Time Frame: 2 years ] [ Designated as safety issue: No ]The primary outcome will be the proportion of patients found to have lymph nodes metastases on pathologic examination. Specifically, the difference in proportion of specimens found to contain nodal metastases using the fat-emulsifying protocol compared to the conventional lymph node processing will be analyzed.
- Total number of lymph nodes and lymph node metastasis [ Time Frame: 2 years ] [ Designated as safety issue: No ]Secondary outcome measures will be: the total number of lymph nodes and the total number of lymph node metastases counted by both techniques and the relationship between the size of lymph node and the presence of metastatic carcinoma.
|Study Start Date:||August 2011|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||August 2013 (Final data collection date for primary outcome measure)|
There will be no separate cohorts in this study. All patients will have their specimens processed by conventional means and by the study method. The conventional means will be the control for the study method.
Show Detailed Description
|Contact: Peter Black, MD||780-475-4111 ext email@example.com|
|Contact: Michael J Metcalfe, MD||778 firstname.lastname@example.org|
|Canada, British Columbia|
|Vancouver General Hospital||Recruiting|
|Vancouver, British Columbia, Canada, V5Z 1M9|
|Contact: Peter Black, MD, FRCP 604-875-4111 ext 55003 email@example.com|
|Sub-Investigator: Charles B Metcalfe, MD|
|Sub-Investigator: Michael J Metcalfe, MD|
|Sub-Investigator: Alan I So, MD|
|Sub-Investigator: Martin E Gleave, MD|
|Sub-Investigator: Blake C Gilks, MD|
|Sub-Investigator: Edward C Jones, MD|
|Principal Investigator:||Peter Black, MD||University of British Columbia|